269 related articles for article (PubMed ID: 18645335)
1. Molecular mechanisms of endothelial dysfunction: from nitric oxide synthesis to ADMA inhibition.
Bermúdez V; Bermúdez F; Acosta G; Acosta A; Añez J; Andara C; Leal E; Cano C; Manuel V; Hernández R; Israili Z
Am J Ther; 2008; 15(4):326-33. PubMed ID: 18645335
[TBL] [Abstract][Full Text] [Related]
2. L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor.
Böger RH; Ron ES
Altern Med Rev; 2005 Mar; 10(1):14-23. PubMed ID: 15771559
[TBL] [Abstract][Full Text] [Related]
3. Arginase: a critical regulator of nitric oxide synthesis and vascular function.
Durante W; Johnson FK; Johnson RA
Clin Exp Pharmacol Physiol; 2007 Sep; 34(9):906-11. PubMed ID: 17645639
[TBL] [Abstract][Full Text] [Related]
4. Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal?
Pernow J; Jung C
Cardiovasc Res; 2013 Jun; 98(3):334-43. PubMed ID: 23417041
[TBL] [Abstract][Full Text] [Related]
5. Nitric oxide dynamics and endothelial dysfunction in type II model of genetic diabetes.
Bitar MS; Wahid S; Mustafa S; Al-Saleh E; Dhaunsi GS; Al-Mulla F
Eur J Pharmacol; 2005 Mar; 511(1):53-64. PubMed ID: 15777779
[TBL] [Abstract][Full Text] [Related]
6. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
Böger RH; Bode-Böger SM
Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410
[TBL] [Abstract][Full Text] [Related]
7. Roles of oxidants, nitric oxide, and asymmetric dimethylarginine in endothelial function.
Siekmeier R; Grammer T; März W
J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):279-97. PubMed ID: 18945874
[TBL] [Abstract][Full Text] [Related]
8. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
Siroká R; Cibulka R; Rajdl D; Racek J
Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
[TBL] [Abstract][Full Text] [Related]
9. Reactive oxygen species and endothelial function--role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases.
Montezano AC; Touyz RM
Basic Clin Pharmacol Toxicol; 2012 Jan; 110(1):87-94. PubMed ID: 21883939
[TBL] [Abstract][Full Text] [Related]
10. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?
Rochette L; Lorin J; Zeller M; Guilland JC; Lorgis L; Cottin Y; Vergely C
Pharmacol Ther; 2013 Dec; 140(3):239-57. PubMed ID: 23859953
[TBL] [Abstract][Full Text] [Related]
11. Secondary endothelial dysfunction: hypertension and heart failure.
Boulanger CM
J Mol Cell Cardiol; 1999 Jan; 31(1):39-49. PubMed ID: 10072714
[TBL] [Abstract][Full Text] [Related]
12. The pivotal role of nitric oxide for vascular health.
Cooke JP
Can J Cardiol; 2004 Aug; 20 Suppl B():7B-15B. PubMed ID: 15309199
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide-dependent endothelial function and cardiovascular disease.
Desjardins F; Balligand JL
Acta Clin Belg; 2006; 61(6):326-34. PubMed ID: 17323842
[TBL] [Abstract][Full Text] [Related]
14. Primary endothelial dysfunction: atherosclerosis.
Shimokawa H
J Mol Cell Cardiol; 1999 Jan; 31(1):23-37. PubMed ID: 10072713
[TBL] [Abstract][Full Text] [Related]
15. Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities.
Kietadisorn R; Juni RP; Moens AL
Am J Physiol Endocrinol Metab; 2012 Mar; 302(5):E481-95. PubMed ID: 22167522
[TBL] [Abstract][Full Text] [Related]
16. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?
Chan NN; Chan JC
Diabetologia; 2002 Dec; 45(12):1609-16. PubMed ID: 12488950
[TBL] [Abstract][Full Text] [Related]
17. Oxidative stress and endothelial nitric oxide bioactivity.
Thomas SR; Chen K; Keaney JF
Antioxid Redox Signal; 2003 Apr; 5(2):181-94. PubMed ID: 12716478
[TBL] [Abstract][Full Text] [Related]
18. Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance.
Toutouzas K; Riga M; Stefanadi E; Stefanadis C
Horm Metab Res; 2008 Sep; 40(9):655-9. PubMed ID: 18792879
[TBL] [Abstract][Full Text] [Related]
19. Impaired flow-mediated dilation with age is not explained by L-arginine bioavailability or endothelial asymmetric dimethylarginine protein expression.
Gates PE; Boucher ML; Silver AE; Monahan KD; Seals DR
J Appl Physiol (1985); 2007 Jan; 102(1):63-71. PubMed ID: 16946027
[TBL] [Abstract][Full Text] [Related]
20. Protective effects of kaempferol against endothelial damage by an improvement in nitric oxide production and a decrease in asymmetric dimethylarginine level.
Xiao HB; Jun-Fang ; Lu XY; Chen XJ; Chao-Tan ; Sun ZL
Eur J Pharmacol; 2009 Aug; 616(1-3):213-22. PubMed ID: 19549512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
